Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab, Propranolol, and mFOLFOX in Advanced Esophageal/GEJ Adenocarcinoma
NCT05651594Phase 2Recruiting
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Mar 2023
- Primary completion
- Mar 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of propranolol in esophageal adenocarcinoma (EAC) and gastroesophageal junction adenocarcinoma, sponsored by Roswell Park Comprehensive Cancer Center. Primary endpoint: Overall Response Rate at 6 months. Started Mar 2023; status: recruiting.
02
Drugs
propranolol
03
Conditions
esophageal adenocarcinoma (EAC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT05651594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05651594.